Normal view MARC view ISBD view

Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy.

MedStar author(s):

Citation: Journal of oncology practice/American Society of Clinical Oncology. 12(10):928-935, 2016 OctPMID: 27858561Institution: Washington Cancer InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Antineoplastic Agents/tu [Therapeutic Use] | *Cytoreduction Surgical Procedures | *Lung Neoplasms/dt [Drug Therapy] | *Lung Neoplasms/su [Surgery] | *Mesothelioma/dt [Drug Therapy] | *Mesothelioma/su [Surgery] | *Peritoneal Neoplasms/dt [Drug Therapy] | *Peritoneal Neoplasms/su [Surgery] | Antineoplastic Agents/ae [Adverse Effects] | Cytoreduction Surgical Procedures/ae [Adverse Effects] | Humans | Lung Neoplasms/di [Diagnosis] | Mesothelioma/di [Diagnosis] | Neoplasm Recurrence, Local/dt [Drug Therapy] | Neoplasm Recurrence, Local/su [Surgery] | Perioperative Care | Peritoneal Neoplasms/di [Diagnosis]Year: 2016 ISSN:

1554-7477

Name of journal: Journal of oncology practiceAbstract: Malignant peritoneal mesothelioma is a rare disease, with approximately 800 new patients per year in the United States. Its natural history is defined by progression restricted to the peritoneal space. In the past, patients with this disease had a limited lifespan of approximately 1 year. Numerous single-institution studies as well as a systematic review have reported median survival of 3 to 5 years with a combination of cytoreductive surgery and hyperthermic perioperative chemotherapy. These markedly improved survival statistics were achieved in experienced centers with 1% mortality and 20% morbidity rates. Data have shown that knowledgeable patient selection is required to prevent patients unlikely to benefit from undergoing these interventions. The conclusion is that patients with peritoneal mesothelioma can experience long-term progression-free survival or significant palliation with cytoreductive surgery plus hyperthermic perioperative chemotherapy. This management plan should be considered the standard of care for properly selected patients with malignant peritoneal mesothelioma at experienced centers around the world.All authors: Alexander HR Jr, Deraco M, Hesdorffer M, Sugarbaker PH, Turaga KKFiscal year: FY2017Digital Object Identifier:

https://dx.doi.org/10.1200/JOP.2016.011908

Date added to catalog: 2017-05-24

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	27858561	Available		27858561

Malignant peritoneal mesothelioma is a rare disease, with approximately 800 new patients per year in the United States. Its natural history is defined by progression restricted to the peritoneal space. In the past, patients with this disease had a limited lifespan of approximately 1 year. Numerous single-institution studies as well as a systematic review have reported median survival of 3 to 5 years with a combination of cytoreductive surgery and hyperthermic perioperative chemotherapy. These markedly improved survival statistics were achieved in experienced centers with 1% mortality and 20% morbidity rates. Data have shown that knowledgeable patient selection is required to prevent patients unlikely to benefit from undergoing these interventions. The conclusion is that patients with peritoneal mesothelioma can experience long-term progression-free survival or significant palliation with cytoreductive surgery plus hyperthermic perioperative chemotherapy. This management plan should be considered the standard of care for properly selected patients with malignant peritoneal mesothelioma at experienced centers around the world.

English